SAN FRANCISCO, CA, USA I December 18, 2018 I Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today ...

Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF ...

DURHAM, NC, USA I March 23, 2016 I Argos Therapeutics, Inc. (ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for ...

HAMBURG, Germany I May 20, 2019 I Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today the signing of a definitive agreement under which Evotec will acquire Just ...

HONG KONG, BEIJING, China and BOSTON, MA, USA I June 6, 2025 I GenEditBio Limited (“GenEditBio”), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions ...

-Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8 th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could ...

Adds IND-ready AI-081, a PD-1/VEGF bispecific antibody with best-in-class potential and clinical-stage assets including next-generation siglec agonist AI-071 Both companies are co-founded by CEO, Yang ...

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, CA, USA I May 15, 2014 I Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical ...

— Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer — SOUTH SAN FRANCISCO, CA, USA I July 2, 2014 I Genentech, a member of the Roche Group (SIX ...

Additional Year of Market Exclusivity Granted Based on Significant Clinical Benefit XGEVA Provides Over Existing Therapies THOUSAND OAKS, CA, USA | July 15, 2011 | Amgen (NASDAQ:AMGN – News) today ...

San Diego, CA, USA I September 8, 2016 I BioTheryX, Inc. (BTX), is developing next-generation drugs that selectively regulate the stability of disease-causing proteins to treat a broad range of ...